MLabs NGS Panels Detects NTRK Fusion Genes in Select Solid Tumor Patients for FDA-approved Vitrakvi® (larotrectinib) Therapy

MLabs next-generation sequencing (NGS) offerings include Solid Tumor, Lung Cancer, Colorectal Cancer, and Melanoma NGS Panels. These NGS tests target 50 genes to detect substitution and insertion/deletion mutations (35 genes), gene amplifications (19 genes), and gene fusions (21 genes) including NTRK gene fusions involving NTRK1, NTRK2, and NTRK3. The TRK inhibitor Vitrakvi® (larotrectinib) was recently FDA-approved for treatment of adult and pediatric patients with solid tumors that have a NTRK gene fusion. NGS is the most comprehensive method to identify NTRK gene fusions, particularly in cases with minimal available tissue. MLabs performs these panels using as little as <1mm2  tissue with a 4% QNS rate. For more information about our tissue requirements for NGS testing visit Less Tissue More Results.  

MLabs NGS panels not only detect NTRK gene fusions, but include many other standard of care and emerging biomarkers in solid tumors. A complete list of genes assessed for mutations, amplifications and fusions is listed below.

Hotspot Mutation Detection      Amplification     Selected Fusion Detection
AKT1 IDH2 ALK FGFR3 ALK RAF1
ALK JAK1 AR FGFR4 RET ERG
AR JAK2 BRAF KIT ROS1 ETV1
BRAF JAK3 CCND1 KRAS NTRK1 ETV4
CDK4 KIT CDK4 MET NTRK2 ETV5
CTNNB1 KRAS CDK6 MYC NTRK3 AXL
DDR2 MAP2K1 EGFR MYCN FGFR1 EGFRvIII
EGFR MAP2K2 ERBB2 (HER2) PDGFRA FGFR2 ERBB2 (HER2)
ERBB2 (HER2) MET FGFR1 PIK3CA FGFR3 PDGFRA
ERBB3 MTOR FGFR2   MET PPARG
ERBB4 NRAS     BRAF  
ESR1 PDGFRA        
FGFR2 PIK3CA        
FGFR3 RAF1        
GNA11 RET        
GNAQ ROS1        
HRAS SMO        
IDH1